Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Tag: FDA

April 29, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1

Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and

Continue reading

April 22, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol® Cyclo™ in Alzheimer’s Disease

Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and

Continue reading

January 14, 2021 Drug delivery / Pharma applications

Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of SBECD-enabled Ganaxolone in CDKL5 Deficiency Disorder (CDD)

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders,

Continue reading

November 9, 2020 Drug delivery / Pharma applications

Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ (SBECD-enabled fosphenytoin)

Ligand Pharmaceuticals Incorporated announced that its partner Sedor Pharmaceuticals, LLC has received approval from the U.S. Food and Drug Administration

Continue reading

October 24, 2020 Drug delivery / Pharma applications

U.S. FDA Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19

— Veklury Is First and Only FDA-Approved Treatment for COVID-19 in the United States — — Veklury Shortened Time to

Continue reading

October 19, 2020 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Phase 3 Pivotal Program Can Begin Enrollment Per US FDA

Cyclo Therapeutics will now proceed in the US with its Phase 3 clinical trial of Trappsol® Cyclo™ for treatment of Niemann-Pick

Continue reading

September 4, 2020 Pharma applications

FDA Expands EUA for SBECD-enabled Remdesivir

Gilead’s Investigational Antiviral Veklury® (Remdesivir) Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of Patients With

Continue reading

August 24, 2020 Pharma applications

FDA Approves New KYPROLIS® (SBECD-enabled carfilzomib) Combination Regimen With DARZALEX® (daratumumab) And Dexamethasone

Approval Based on the CANDOR and EQUULEUS Studies in Patients With Relapsed/Refractory Multiple Myeloma Amgen today announced the U.S. Food and

Continue reading

August 24, 2020 Drug delivery / Pharma applications

Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-07 for the Acute Treatment of Migraine

Axsome Therapeutics, a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced that it

Continue reading

August 6, 2020 Pharma applications

Breakthrough Therapy Designation Granted for SBECD-enabled Pevonedistat

Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for its SBECD

Continue reading

Posts pagination

«Previous Posts 1 2 3 4 Next Posts»

Recent Posts

  • Positively Charged Fluorine-Free Cyclodextrin Nanosponges for PFAS Removal
  • Impact of Cholesterol Depletion by methyl BCD on Dopamine Transmission Dynamics in Brain
  • Special Issue “Cyclodextrin-Functionalized Materials for Drug Delivery, Pharmaceutical and Medical Applications”
  • Cyclodextrin-Based Oral Solution of Ursodeoxycholic Acid Using a Ready-to-Use Vehicle
  • Cyclodextrin-based electrochemical sensors for PFAS detection

Tags

alpha-CD Alzheimer disease atherosclerosis Cancer therapy Captisol Cholesterol Clinical trial conference Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems electrospinning FDA Food gamma-CD Gilead HPBCD hydrogel methyl BCD Nanoparticles Niemann Pick Disease RAMEB remdesivir review SBECD Special issue Synthesis

Follow Us

  • LinkedIn
  • X
  • Facebook

Categories

  • Agriculture (27)
  • Analysis (72)
  • CD as API (351)
  • CD derivatives (423)
  • Cosmetics and toilettry (52)
  • Diagnosis (13)
  • Drug delivery (803)
  • E-ducation (63)
  • Environmental (141)
  • Events (236)
  • Food (229)
  • Gene delivery (22)
  • Household products (5)
  • Household products (1)
  • In Hungarian (4)
  • Life sciences (44)
  • Non-pharma applications (409)
  • Other industrial use (110)
  • Pharma applications (1,201)
  • Supramolecular systems (44)
  • Uncategorized (161)

Top Posts

  • Positively Charged Fluorine-Free Cyclodextrin Nanosponges for PFAS Removal
  • Impact of Cholesterol Depletion by methyl BCD on Dopamine Transmission Dynamics in Brain
  • CDs for the removal of PFAS; A review
  • How air fresheners work?
  • European Symposium on Controlled Drug Delivery
  • Mallinckrodt gave up further development of adrabetadex (VTS-270; HPBCD)
  • Call for Book Chapters – Cyclodextrin-Based Books (Wiley & Springer)
  • Deadline for early bird registration to ICS-22: 31 July
  • Bridion® injection now approved for patients of all ages
  • Practical Considerations about the Cyclodextrin Solubilities – A Quickstart Guide for Newbies

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 4,476 other subscribers
Loading Comments...